![]()
| As of Friday, November 13th: |
As of October 1st, the earnings growth rate was at -24.7%.Of the 463 S&P 500 companies who have reported Q3, 80% beat estimates, 6% were in-line, and 14% were below estimates. The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -13.8%. (Data provided by Thomson Reuters)
LATEST EARNINGS RESULTS
- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- Today's Market Action
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Israel Going Green
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Low Interest Rate Investing
- Inside Wal-Mart's Acai Berry Juice Maker
- China's Role as Lender Alters Dynamics for United States
- Seeking Innovation in Health Care
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
Bristol-Myers Squibb on Thursday posted quarterly earnings that beat forecasts, helped by higher sales of blood clot preventer Plavix and schizophrenia treatment Abilify, and the company announced an additional $1 billion in planned cost cuts.
The New York-based drugmaker earned $764 million, or 38 cents per share, in the second quarter, compared with $706 million, or 36 cents per share, in the year-earlier period.
Excluding special items, such as discontinued operations, Bristol-Myers [BMY
Loading...
()
] earned 43 cents per share.
Analysts on average expected 40 cents per share, according to Reuters Estimates.
"The quarterly beat came primarily from stronger-than-expected Abilify sales, coupled with solid cost-containment," J.P. Morgan analyst Chris Schott said in a research report.
Global company sales from continuing operations jumped 16 percent to $5.2 billion, above the $5.09 billion Reuters Estimates forecast.
They would have risen 11 percent if not for favorable foreign exchange factors.
Bristol said it is on track to achieve $1.5 billion in planned cumulative savings by 2010 from a productivity initiative begun late last year.
Moreover, the company said it is taking steps to create an additional $1 billion in cost savings by 2012.
The cost savings could somewhat help offset expected plunging sales of Plavix when the $5 billion-a-year anti-clot drug faces U.S. generic competition by May 2012.
The savings would also help Bristol-Myers better contend with lower sales of Plavix should U.S. regulators approve Eli Lilly's [LLY
Loading...
()
] rival Effient (prasugrel) brand.
A decision on the new anti-clot medicine could come by late September.
Global sales of Plavix jumped 17 percent to $1.39 billion in the second quarter, after generic supplies of the medicine that had competed with Plavix for about a year in the United States became exhausted.
A federal court has banned continued shipments of the generic, saying it infringed Plavix patents held by Bristol's marketing partner Sanofi-Aventis [SNY
Loading...
()
] .
Sales of HIV treatment Reyataz, helped by its convenient once-daily dosing, surged 28 percent to $324 million, while sales of cancer drug Erbitux rose 21 percent to $196 million.
Abilify continued to gain ground, in part because it does not cause worrisome weight gains seen with rival treatments, with sales jumping 28 percent to $529 million.
Bristol-Myers reaffirmed it expects 2008 earnings from continuing operations, excluding special items, of between $1.60 and $1.70 per share.
That would reflect growth of up to 14.8 percent from last year.
The drugmaker also reaffirmed it expects earnings per share to grow by at least 15 percent annually through 2010.
- Disney Profit, Sales Top Forecasts; Shares Jump
Walt Disney shares rose in after-hours trading Thursday after the company reported earnings and revenue that beat analysts' expectations.
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
Nordstrom reported earnings that missed analysts expectations by a penny but beat on revenue, causing the company's shares to fall in after-hours trading.
- Wal-Mart Holiday Forecast Light, Profit Beats
Wal-Mart Stores posted a higher-than-expected quarterly profit, but forecast earnings during the key holiday quarter that could miss Wall Street estimates as its customers face rising unemployment.
- Disney Profit, Sales Top Forecasts; Shares Jump
- Kohl's Profit Beats Street, But Outlook Falls Short
Department store operator Kohl's Corp reported a larger-than-expected quarterly profit Thursday, but gave an outlook below Wall Street estimates for the period that includes the key holiday season.
- Kohl's Profit Beats Street, But Outlook Falls Short
- Vivendi Profit Up More Than 5%, Keeps 2009 Goals
- Cost Cuts Help BT to Raise Full-Year Guidance
- Applied Materials Profit, Sales Top Wall Street Forecasts
- Macy's Loss Beats Estimates, But Shares Fall on Outlook
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Tyco International Profit Falls Less Than Expected
- EA Profit Beats Street, Announces Job Cuts
- Priceline Crushes Profit Forecasts; Shares Jump
- Berkshire Hathaway Says Net Income Tripled
- Sun Micro Sales Fall as Oracle Deal Remains Delayed
- AIG in the Black Again, Operating Profit Tops View
- Starbucks Profit Beats Forecasts; Shares Rise
- Fannie Mae Seeks $15 Billion in Aid After Posting Loss
- Nvidia Profit, Sales Top Wall Street's Forecast
- CBS Beats Expectations on Improved Ad Market








